CAMBRIDGE, England--(BUSINESS WIRE)--Semarion Ltd, a University of Cambridge spin-out company from the Cavendish Laboratory combining materials engineering and cell biology to tackle unmet drug screening needs, today introduced its SemaCyte® Multiplexing Platform, an expansion to the existing SemaCyte Microcarrier platform to utilize optical barcoding to accelerate screening processes during in vitro drug discovery.

英国剑桥--（商业新闻短讯）--Semarion Ltd是剑桥大学卡文迪什实验室的一家螺旋输出公司，结合材料工程和细胞生物学来解决未满足的药物筛选需求，今天推出了其SemaCyte®多路复用平台，这是对现有SemaCyte微载体平台的扩展，可利用光学条形码来加速体外药物发现过程中的筛选过程。

Designed specifically to augment microplate-based high-content imaging (HCI) approaches, the platform enables in situ multiplexing of adherent cells using the Company’s proprietary microcarriers, SemaCytes, to enhance both the quality and speed of data generation..

该平台专门用于增强基于微孔板的高内容成像（HCI）方法，使用该公司专有的微载体SemaCytes实现贴壁细胞的原位多路复用，以提高数据生成的质量和速度。。

The SemaCyte Multiplexing Platform uses optical barcodes to tag and differentiate individual cells and cell types while preserving natural morphology, with each microcarrier capable of carrying millions of unique identifiers. Each barcode can be viewed using brightfield microscopy, and digitally deconvoluted using the Company’s Semalyse software, included within the platform.

SemaCyte多路复用平台使用光学条形码标记和区分单个细胞和细胞类型，同时保留自然形态，每个微载体能够携带数百万个唯一标识符。可以使用明场显微镜查看每个条形码，并使用平台中包含的该公司的Semalyse软件进行数字解卷积。

Cells can be pooled for complex screening workflows, such as oncology panel screens, and enables individual cells to be precisely tracked and studied, facilitating increased throughput and more robust datasets to be generated, and shown to reduce cost and time requirements by up to 6- and 10-fold, respectively.

可以将细胞汇集起来用于复杂的筛选工作流程，例如肿瘤学面板筛选，并使单个细胞能够被精确跟踪和研究，从而有助于提高吞吐量和生成更强大的数据集，并显示出可将成本和时间要求分别降低6倍和10倍。

The Multiplexing Platform can be used across a broad range of applications, including target identification, compound screening and compound profiling..

多路复用平台可用于广泛的应用，包括目标识别、化合物筛选和化合物分析。。

The Multiplexing Platform has been developed to further leverage Semarion’s innovative microcarrier technology, SemaCytes, in advancing drug discovery workflows. SemaCytes are a novel class of cell carriers created to address fundamental limitations in adherent cell assaying workflows using microchip fabrication technologies, nanomagnetism, and smart materials.

开发多路复用平台是为了进一步利用Semarion的创新微载体技术SemaCytes来推进药物发现工作流程。SemaCytes是一类新型细胞载体，用于解决使用微芯片制造技术，纳米磁性和智能材料的贴壁细胞测定工作流程中的基本限制。

These well-shaped, magnetically steerable carriers enable controlled movement of small colonies of adherent cell types and can be directly assayed or stably cryopreserved for prolonged periods without the need for complex protocols and specialized equipment. This unique approach to microcarrier design provides users a streamlined route to conducting cell assays and offers significant improvements to throughput, resource efficiency and flexibility..

这些形状良好的磁性可操纵载体能够控制粘附细胞类型的小菌落的运动，并且可以直接测定或长时间稳定冷冻保存，而不需要复杂的方案和专用设备。这种独特的微载体设计方法为用户提供了进行细胞分析的简化途径，并显着提高了吞吐量，资源效率和灵活性。。

Following the success of the Early Adopter Program for the SemaCyte Microcarrier Platform in October 20231, researchers can now apply for early access to the Multiplexing Platform. As part of the program, Semarion will work in partnership with early adopters to integrate the platform into existing workflows.

随着SemaCyte微载体平台的早期采用者计划于20231年10月取得成功，研究人员现在可以申请早期访问多路复用平台。作为该计划的一部分，Semarion将与早期采用者合作，将平台集成到现有的工作流程中。

To apply to be part of the Early Adopter Program, please visit the following link: https://www.semarion.com/early-adopter/.

要申请成为早期采用者计划的一部分，请访问以下链接：https://www.semarion.com/early-adopter/.

Dr. Jeroen Verheyen, Co-Founder and CEO, Semarion, commented: “We saw a fantastic response to our Early Adopter Program for the SemaCyte platform in October 2023, and are pleased to be able to expand the program now to accommodate the next iteration of that technology, the SemaCyte Multiplexing Platform.

Semarion联合创始人兼首席执行官Jeroen Verheyen博士评论道：“2023年10月，我们看到SemaCyte平台的早期采用者计划得到了极好的回应，很高兴现在能够扩展该计划，以适应该技术的下一次迭代，即SemaCyte多路复用平台。

Building on the success of our innovative microcarrier technology, the Multiplex Platform enables diverse mixtures of cells and cell types to be individually tagged with unique, optical barcodes, and pooled to maximise screening throughput, whilst significantly reducing cost and time requirements.”.

在我们创新的微载体技术取得成功的基础上，多重平台使细胞和细胞类型的不同混合物能够用独特的光学条形码单独标记，并合并以最大程度地提高筛选吞吐量，同时显着降低成本和时间要求。”。

Dr. Del Trezise, Advisor and Non-Executive Director, Semarion, said: “The SemaCyte Multiplexing Platform has been specifically designed to address the limitations of image-based assay techniques. Leveraging optically-barcoded microcarriers, each capable of carrying over a million identifiers, the Platform enables researchers to conduct simultaneous image analysis of hundreds of distinct cell populations from within a single well – demonstrating immense promise for enhancing the efficiency of cell panel screens.”.

Semarion顾问兼非执行董事Del Trezise博士说：“SemaCyte多路复用平台是专门为解决基于图像的检测技术的局限性而设计的。该平台利用光学条形码微载体，每个微载体能够携带100多万个标识符，使研究人员能够在一个孔内同时对数百个不同的细胞群进行图像分析，这为提高细胞面板屏幕的效率提供了巨大的希望。”。

Dr. Erica Bello, Head of the Target Discovery Group, The Milner Therapeutics Institute, commented: “We are currently implementing arrayed CRISPR screens to validate targets associated with resistance to a pan-AKT inhibitor drug, AZD5363, which were identified in a pooled CRIPSR screen. We are going to work with Semarion to see whether their exciting platform can be used to multiplex cancer cell lines in arrayed CRISPR screens, which could lead to substantial time and cost savings.”.

Milner Therapeutics Institute Target Discovery Group负责人Erica Bello博士评论道：“我们目前正在实施阵列CRISPR筛选，以验证与泛AKT抑制剂药物AZD5363耐药相关的靶标，这些靶标是在合并的CRIPSR筛选中确定的。我们将与Semarion合作，看看他们令人兴奋的平台是否可以用于阵列CRISPR筛选中的癌细胞系的多重化，这可能会节省大量时间和成本。”。

Semarion will be showcasing the SemaCyte Multiplexing Platform at the TechBio Breakthrough Zone of ELRIG Research and Innovation 2024, taking place 20-21 March at the University of Manchester.

Semarion将于3月20日至21日在曼彻斯特大学ELRIG Research and Innovation 2024的TechBio突破区展示SemaCyte多路复用平台。

For more information about the SemaCyte Multiplexing Platform, visit: www.semarion.com/semaplex/.

有关SemaCyte多路复用平台的更多信息，请访问：www.semarion.com/semaplex/。

https://www.semarion.com/semarion-announces-early-adopter-programme-for-semacyte-microcarrier-platform/

https://www.semarion.com/semarion-announces-early-adopter-programme-for-semacyte-microcarrier-platform/